Skip to main content
Veterinary Medicines

Adrestan 30 mg hard capsules

Authorised
  • Trilostane

Product identification

Medicine name:
Adrestan 30 mg hard capsules
Adrestan 30 mg Capsule, hard
Adrestan 30 mg Gélule
Adrestan 30 mg Hartkapsel
Active substance:
  • Trilostane
Target species:
  • Dog
Route of administration:
  • Oral use

Product details

Active substance and strength:
  • Trilostane
    30.00
    milligram(s)
    /
    1.00
    Capsule
Pharmaceutical form:
  • Capsule, hard
Withdrawal period by route of administration:
  • Oral use
    • Dog
Anatomical therapeutic chemical veterinary (ATCvet) codes:
  • QH02CA01
Authorisation status:
  • Valid
Authorised in:
  • Belgium
Package description:
  • Three PVC-PVdc/aluminium foil blister strips each containing 10 capsules.

Additional information

Entitlement type:
  • Marketing Authorisation
Marketing authorisation holder:
  • Dechra Regulatory B.V.
Marketing authorisation date:
Manufacturing sites for batch release:
  • Genera d.d.
Responsible authority:
  • FAMHP
Authorisation number:
  • BE-V499111
Date of authorisation status change:
Reference member state:
  • Ireland
Procedure number:
  • IE/V/0503/002
Concerned member states:
  • Belgium
  • France
  • Italy
  • Netherlands
  • Portugal
  • Spain
  • United Kingdom (Northern Ireland)

Documents

Summary of Product Characteristics

English (PDF)
Published on: 3/05/2024
Download
Dutch (PDF)
Published on: 22/03/2022
French (PDF)
Published on: 22/03/2022

Package Leaflet

This document does not exist in this language (English). You can find it in another language below.
Dutch (PDF)
Published on: 22/03/2022
French (PDF)
Published on: 22/03/2022
German (PDF)
Published on: 22/03/2022
How useful was this page?:
No votes yet
"Please do not include any personal data, such as your name or contact details. If you do, you consent to the processing of that data in accordance with EMA’s Privacy Statement concerning requests for information or access to documents. If you would like a reply from EMA, please Send a question to EMA instead."